18 and older, any sex, with Chronic Otitis Media. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number and Type of Contacts With Health Care ProvidersPrimary· From primary tympanoplasty to time of enrolment, up to 13 years
Contacts are obtained from medical records, counted and categorized.
Contact for 1 surgical procedure
Group
Value
95% CI
Observational Cohort
45
Contact for 2 surgical procedures
Group
Value
95% CI
Observational Cohort
14
Contact for 3 surgical procedures
Group
Value
95% CI
Observational Cohort
5
Contact for 4 surgical procedures
Group
Value
95% CI
Observational Cohort
3
Contact for more than four surgical procedures
Group
Value
95% CI
Observational Cohort
2
Contact for 2 audiograms
Group
Value
95% CI
Observational Cohort
45
Contact for 3 audiograms
Group
Value
95% CI
Observational Cohort
5
Contact for 4 audiograms
Group
Value
95% CI
Observational Cohort
3
Number and Type of Interventions and/or ProceduresPrimary· From primary tympanoplasty to time of enrolment, up to 13 years
Medical examinations, surgical procedures and hearing rehabilitation are obtained from medical records, counted and categorized.
CT scan of the temporal bone and/or sinuses
Group
Value
95% CI
Observational Cohort
12
MRI of the temporal bone or the brain
Group
Value
95% CI
Observational Cohort
23
another medical examination
Group
Value
95% CI
Observational Cohort
14
primary tympanoplasty
Group
Value
95% CI
Observational Cohort
65
revision surgeries
Group
Value
95% CI
Observational Cohort
25
planned staged or second look surgeries
Group
Value
95% CI
Observational Cohort
18
Number and Type of Medications and TherapiesPrimary· From primary tympanoplasty to time of enrolment, up to 13 years
Medications are obtained from medical records, counted and categorized. Therapies from medical records are listed.
Antiinfective
Group
Value
95% CI
Observational Cohort
20
Analgesics and anesthetics
Group
Value
95% CI
Observational Cohort
1
Anilides
Group
Value
95% CI
Observational Cohort
14
Antivertigo preparations
Group
Value
95% CI
Observational Cohort
3
Benzodiazepine derivatives
Group
Value
95% CI
Observational Cohort
1
Combinations of penicillins, incl. beta-lactamase inhibitors
Group
Value
95% CI
Observational Cohort
4
Corticosteroids
Group
Value
95% CI
Observational Cohort
5
Corticosteroids and antiinfectives in combination
Group
Value
95% CI
Observational Cohort
12
Hearing Performance Assessed Via an AudiogramSecondary· Up to 12 months prior to primary tympanoplasty
PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.
Air Conduction
Group
Value
95% CI
Observational Cohort
53.2
± 19.64
Bone Conduction
Group
Value
95% CI
Observational Cohort
23.8
± 14.76
Hearing Performance Assessed Via an AudiogramSecondary· Within 12 months after primary tympanoplasty
PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.
Air Conduction
Group
Value
95% CI
Observational Cohort
58.7
± 14.9
Bone conduction
Group
Value
95% CI
Observational Cohort
25.3
± 14.85
Hearing Performance Assessed Via an AudiogramSecondary· Up to 6 years prior to study enrollment
PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.
Air conduction
Group
Value
95% CI
Observational Cohort
56.7
± 21.16
Bone conduction
Group
Value
95% CI
Observational Cohort
25.2
± 13.89
Socio-economic Status and Health Care Data Via the Client Service Receipt Inventory (CSRI) SurveySecondary· At enrolment
Demographic data, medical history, hearing rehabilitation, health care utilisation related to ear infection and hearing difficulties and employment information data are collected.
married/living as married
Group
Value
95% CI
Observational Cohort
41
single
Group
Value
95% CI
Observational Cohort
14
widowed
Group
Value
95% CI
Observational Cohort
7
divorced/separated
Group
Value
95% CI
Observational Cohort
6
living with spouse/partner and children
Group
Value
95% CI
Observational Cohort
24
living with spouse/partner without children
Group
Value
95% CI
Observational Cohort
19
living alone
Group
Value
95% CI
Observational Cohort
13
living with their parents
Group
Value
95% CI
Observational Cohort
6
Self-reported Health Status and Health Related Quality of Life Via the Health Utilities Index Mark III (HUI3) Questionnaire.Secondary· At enrolment
HUI provides descriptive evidence on multiple dimensions of health status, a score for each dimension of health and an overall Health Related Quality of life score. The HUI3 classification system is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition and Pain - each with 5 or 6 levels of ability/disability The scoring systems provide utility (preference) scores on a generic scale where 0.00 indicates death and 1.00 indicates perfect health.
Overall
Group
Value
95% CI
Observational Cohort
0.7
± 0.28
Vision
Group
Value
95% CI
Observational Cohort
0.9
± 0.17
Hearing
Group
Value
95% CI
Observational Cohort
0.8
± 0.29
Speech
Group
Value
95% CI
Observational Cohort
0.9
± 0.15
Dexterity
Group
Value
95% CI
Observational Cohort
1
± 0.11
Emotion
Group
Value
95% CI
Observational Cohort
0.9
± 0.16
Cognition
Group
Value
95% CI
Observational Cohort
0.9
± 0.14
Pain
Group
Value
95% CI
Observational Cohort
0.9
± 0.19
Self-reported Health Related Quality of Life of Participants With COM Via the Chronic Otitis Media Outcome Test-15 (COMOT-15) Questionnaire.Secondary· At enrolment
COMOT-15 measures Health Related Quality of life of participants with COM. It consists of three subscales: ear symptoms, hearing function, and mental health forming the overall score. In addition, two questions related to COM are asked: one on the general evaluation of quality of life and one on the frequency of doctor visits in the last six months. The total score and the sub-scores are transformed to a 0-100 scale by dividing the sum of the raw scores of the items by the sum of spans of the items, then multiplying by 100. A higher score indicates a worse health-related quality of life.
Overall
Group
Value
95% CI
Observational Cohort
43
± 18.25
Ear symptoms
Group
Value
95% CI
Observational Cohort
29.4
± 20.28
Hearing function
Group
Value
95% CI
Observational Cohort
65
± 22.84
Mental Health
Group
Value
95% CI
Observational Cohort
46.5
± 27.31
Self-reported Auditory Disability Via the Speech, Spatial and Qualities of Hearing Scale (SSQ-12) QuestionnaireSecondary· At enrolment
SSQ-12 measures speech, spatial and hearing experiences. The total(overall) score summarizes these parameters. A scale from 0 to 10 is used. A mark 0 means "be quite unable to do or experience what is described" and a mark 10 means "be perfectly able to do or experience what is described in the question".
Group
Value
95% CI
Observational Cohort
5.5
± 2.18
Chronic Otitis Media Outcome Test -15 (COMOT-15) Questionnaire in German, French and SpanishSecondary· At enrollment
Mean score of Chronic Otitis Media Outcome Test -15 (COMOT-15) in German, French and Spanish (0-100 scale). This questionnaire consists of 15 questions that query 3 subscales: ear symptoms, hearing function, and mental health. Additionally, it includes a question about quality of life and specialist doctor visit frequency.
The total score is summed, transformed and presented on a 0 - 100 scale where 0 is a good outcome and 100 is the worst possible outcome.
German
Group
Value
95% CI
Observational Cohort
36.8
± 14.76
French
Group
Value
95% CI
Observational Cohort
46.3
± 22.73
Spanish
Group
Value
95% CI
Observational Cohort
45
± 17.12
Sponsor's own description
The objective of this multicentre study is to evaluate the standard of care of participants diagnosed with Chronic Otitis Media that have already gone through a first middle ear surgery but still have at least a moderate hearing loss. The study has a retrospective part (extraction of medical chart data) and a prospective part with a survey and three questionnaires collecting data on the use of health care services, on health related quality of life and hearing performance.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT04396145 — The Effects of Chronic Otitis Surgery on SVV
· active not recruiting
Other Cochlear trials
Trials by the same sponsor.
NCT07077070 — Investigating Electrical Categorical Loudness Scaling Using a Mobile Research App in Experienced Adult Cochlear Implant
· NA
· completed
NCT07156461 — Hearing Outcomes With the Osia 3 Sound Processor Compared to the Osia 2 Sound Processor in Adult Osia Implant Recipients
· NA
· completed
NCT06338670 — Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users
· NA
· completed
NCT06298396 — Investigating Stimulation Parameter and Electrode Mode Changes on Speech Perception in Experienced Adult Cochlear Implan
· NA
· completed
NCT06100393 — New Algorithms to Signal Processing for Speech Enhancement in Adult Cochlear Implant Recipients.
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cochlear
Last refreshed: 7 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04864912.